Monoclonal antibodies for Alzheimer’s disease are lab-engineered proteins designed to latch onto and help clear amyloid-beta, the sticky protein that accumulates into plaques in the brains of people with Alzheimer’s. Two of these drugs, lecanemab and donanemab, have shown they can slow cognitive decline by roughly 25 to 35 percent in large clinical trials involving people with early-stage disease. That is a meaningful shift after decades of failed Alzheimer’s drug trials, but it is also a complicated story involving serious side effects, steep costs, and real uncertainty about how much patients notice the difference in daily life.
How These Antibodies Work
The basic idea is straightforward: if amyloid-beta plaques are contributing to brain damage, removing them should help. Monoclonal antibodies are proteins engineered to recognize and bind to specific targets. In Alzheimer’s, the targets are various forms of amyloid-beta, from small soluble clumps called oligomers and protofibrils to the large, mature plaques deposited in brain tissue. Once the antibody locks on, the brain’s immune cells, primarily microglia, are recruited to engulf and digest the debris.1Nature Index. Monoclonal Antibody Therapies in Alzheimer’s Disease
Not all amyloid antibodies are created equal. Earlier drugs like solanezumab targeted the soluble, monomeric form of amyloid-beta and failed in trials despite successfully reducing free amyloid levels in blood. Newer agents like lecanemab were designed with greater selectivity for protofibrillar forms, which are increasingly recognized as the most toxic species driving synaptic damage.2Nature Index. Monoclonal Antibody Therapies in Alzheimer’s Disease That shift in targeting appears to have made the difference between drugs that clear amyloid without clinical benefit and drugs that produce measurable slowing of decline.
The Drugs That Have Made It to Market
Three amyloid-targeting monoclonal antibodies have received FDA approval, though their trajectories could hardly be more different.
Aducanumab, marketed as Aduhelm, was the first, receiving accelerated approval in 2021 amid enormous controversy. The FDA’s own statistical reviewers reached primarily negative conclusions about the clinical data, while the agency’s clinical reviewers were more positive. Two large phase 3 trials produced contradictory results: one showed benefit and the other did not, and much of the divergence between them remained unexplained.3PubMed Central. Avoiding future controversies in the Alzheimer’s disease space through understanding the aducanumab data and FDA review Medicare initially limited coverage, and Biogen eventually pulled the drug from the market in early 2024. Aducanumab’s legacy is mostly as a cautionary tale about the gap between plaque clearance and clinical improvement.
Lecanemab, sold as Leqembi, received full FDA approval in July 2023 on much stronger footing. In its pivotal trial of nearly 1,800 people with early Alzheimer’s, those receiving lecanemab showed significantly less cognitive decline over 18 months on the primary outcome measure compared to placebo. The study also found substantially greater reductions in brain amyloid burden with lecanemab.4PubMed. Lecanemab in Early Alzheimer’s Disease An open-label extension study found that the drug’s suppression of amyloid and its slowing of clinical decline on measures of cognition, function, and quality of life continued out to 36 months.5PubMed Central. Long-term safety and efficacy of lecanemab in early Alzheimer’s disease: Results from the clarity AD open-label extension study
Donanemab, developed by Eli Lilly and approved in 2024, takes a slightly different approach. It specifically targets an epitope found only on mature amyloid plaques already deposited in the brain. One striking feature of the donanemab data is that once patients achieved substantial plaque clearance, treatment could be stopped. Among participants who reached very low amyloid levels by 24 weeks and discontinued the drug, the clearance was sustained with only minimal reaccumulation over the following year. Modeling suggested it could take roughly four years for amyloid to reaccumulate to a meaningful threshold after stopping.6JAMA Neurology. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial This raises the appealing possibility that donanemab might work more like a time-limited course of treatment rather than an indefinite infusion regimen.
How Much Do They Actually Help?
This is probably the most important question for patients and families, and the most contentious one in the field. A meta-analysis pooling data across anti-amyloid antibody trials in early Alzheimer’s found statistically significant reductions in the rate of cognitive decline on standard clinical scales.7PubMed. Efficacy of anti-amyloid-ß monoclonal antibody therapy in early Alzheimer’s disease: a systematic review and meta-analysis Across the board, these drugs appear to slow decline by about 25 to 35 percent compared to placebo, a figure that has been characterized as clinically meaningful in terms of preserving cognitive function and delaying the transition to more severe phases of the disease.8PubMed Central. Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
But “slowing decline by a third” is not the same as stopping it or reversing it. Over 18 months, the treated group and the placebo group both got worse; the treated group just got worse more slowly. Whether patients and caregivers can perceive that difference in everyday life is genuinely debated. The benefit amounts to buying time, not restoring lost function. How much time depends on assumptions. Modeling studies that extrapolated from the positive trial results estimated that these treatments could delay the onset of severe dementia by anywhere from a few months in a conservative scenario to roughly two to four years in an optimistic one.9PubMed Central. Scenarios for the long-term efficacy of amyloid-targeting therapies in the context of the natural history of Alzheimer’s disease
There is also growing evidence that the benefit depends heavily on when treatment starts and how far the disease has already progressed. A systematic review found that participants with lower tau pathology, a marker of earlier disease, experienced a substantially larger reduction in clinical progression than those with more advanced tau burden.10PubMed Central. The Efficacy of Anti-amyloid Monoclonal Antibodies in Early Alzheimer’s Dementia: A Systematic Review This fits with the broader pattern suggesting that amyloid clearance matters most before extensive downstream damage has occurred. In practice, it means these drugs are being positioned for early-stage Alzheimer’s, not moderate or advanced disease.
ARIA and the Safety Trade-Off
The most significant safety concern with amyloid-targeting antibodies is a set of brain changes visible on MRI collectively called amyloid-related imaging abnormalities, or ARIA. These come in two forms: ARIA-E, which involves brain swelling and fluid leakage, and ARIA-H, which involves tiny brain bleeds or superficial iron deposits. Both result from the treatment disrupting the integrity of small blood vessels in the brain as amyloid is cleared from vessel walls.11PubMed Central. Amyloid-Related Imaging Abnormalities in the Era of Anti-Amyloid Beta Monoclonal Antibodies for Alzheimer’s Disease
Most cases of ARIA show up on scheduled MRI scans without the patient noticing anything. But some people develop headaches, confusion, dizziness, nausea, or seizures, and in rare cases ARIA has been fatal.12PubMed Central. Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications A published case report described a woman treated with lecanemab who died from cerebral arteritis, an inflammatory reaction in the brain’s blood vessels linked to the drug’s interaction with pre-existing amyloid deposits in those vessels.13Nature Communications. Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer’s disease
The rates of ARIA vary considerably between drugs. In trials of lecanemab, ARIA-E occurred in about 12 percent of treated patients and ARIA-H in about 17 percent. Those rates were lower than for aducanumab, which saw ARIA-E in roughly 35 percent and ARIA-H in about 19 percent of treated patients.14PubMed Central. Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications ARIA tends to occur early in the treatment course and is more common in people who carry one or more copies of the APOE ε4 gene variant.15PubMed. Amyloid-Related Imaging Abnormalities: An Update
Who Is at Higher Risk
Three factors consistently predict a higher chance of developing ARIA: being treated with an anti-amyloid antibody (obviously), having pre-existing tiny brain bleeds visible on MRI, and carrying the APOE ε4 gene variant.16PubMed Central. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics Additional risk comes from having cerebral amyloid angiopathy, a condition where amyloid deposits build up in the walls of brain blood vessels, as well as comorbidities like high blood pressure and a history of ischemic stroke.17PubMed Central. Amyloid-related imaging abnormalities (ARIA) in Alzheimer’s disease: from pathophysiology to individualized risk assessment
The APOE ε4 issue is especially thorny because this same gene variant is the strongest known genetic risk factor for developing Alzheimer’s in the first place. About 60 to 75 percent of Alzheimer’s patients carry at least one copy. People who are homozygous (two copies) face the highest ARIA risk and, notably, did not clearly benefit from treatment in subgroup analyses of both the lecanemab and donanemab phase 3 trials.18Nature Communications. Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer’s disease Appropriate use recommendations for lecanemab advise APOE genotyping before starting treatment so that doctors and patients can have an informed conversation about the balance of risk and potential benefit.19The Journal of Prevention of Alzheimer’s Disease. Lecanemab: Appropriate Use Recommendations
Because of the need for regular MRI monitoring to catch ARIA early, and the intravenous infusion schedule that currently defines treatment, receiving these drugs requires a level of medical infrastructure that not all clinics can provide. One implementation study found that designating a dedicated project manager and building electronic medical record tools made the process workable, but the logistics are real.20PubMed Central. A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer’s Disease
What Treatment Looks Like in Practice
Currently, lecanemab is given as an intravenous infusion every two weeks. This means regular trips to an infusion center, plus scheduled MRI scans to monitor for ARIA, especially in the first several months. For many patients and caregivers, that is a substantial time commitment on top of managing the disease itself.
A subcutaneous formulation of lecanemab is in development, which would allow the drug to be injected under the skin rather than infused intravenously. Early data show that a subcutaneous injection by vial or autoinjector produces comparable steady-state drug concentrations to the IV version, and modeling predicts similar amyloid-lowering and clinical effects.21Alzheimer’s & Dementia. Development of Subcutaneous Lecanemab: Establishing the Comparability of Subcutaneous and Intravenous Lecanemab Formulations If approved, a self-administered injection at home would remove one of the major practical barriers to treatment, though MRI monitoring would still be necessary.
The Cost Problem
Monoclonal antibodies for Alzheimer’s are expensive, and the financial picture is complicated by the sheer number of people who could be eligible. After lecanemab received full FDA approval, Medicare began providing broad coverage. For patients with supplemental insurance through Medigap, Medicare Advantage, Medicaid, or commercial plans, out-of-pocket costs are expected to range from nothing to a few dollars per day. Those on Medicare without supplemental coverage face about 20 percent of the drug’s cost as coinsurance. A patient assistance program exists for people without insurance or those who meet certain financial criteria.22PubMed Central. Lifetime cost-effectiveness of lecanemab for early Alzheimer’s disease
The bigger issue is systemic. Estimates suggest that if about 100,000 people used lecanemab by the third year of availability, annual Medicare Part B spending could reach around $2.7 billion. If adoption grows to 5 or 10 percent of Alzheimer’s patients, costs could balloon to $9 billion or nearly $18 billion per year.23PubMed Central. Lifetime cost-effectiveness of lecanemab for early Alzheimer’s disease And because lecanemab is a biologic, its manufacturer is exempt from Medicare drug price negotiations for 13 years after approval, meaning the current price structure is locked in until roughly 2036.
Cost-effectiveness analyses have found that these drugs are expensive relative to the benefit they provide by conventional health-economics standards. One early modeling study estimated that donanemab’s cost-effectiveness ratio was around $176,000 to $193,000 per quality-adjusted life year gained, while aducanumab (at its original price) was far worse, near $1 million per quality-adjusted life year.24JAMA Neurology. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US The commonly cited threshold for acceptable cost-effectiveness in the U.S. is around $100,000 to $150,000 per quality-adjusted life year. These drugs are above that bar, though the gap is smaller for donanemab than it was for aducanumab.
Why So Many Earlier Antibodies Failed
The history of amyloid-targeting antibodies is littered with failures, and understanding why matters for evaluating the current generation. The amyloid hypothesis, first proposed in 1991, suggested that amyloid-beta accumulation was the primary driver of Alzheimer’s pathology. Over the following three decades, multiple antibodies designed around this idea failed in large trials. Solanezumab, which targeted soluble monomeric amyloid, reduced circulating amyloid by over 90 percent but produced no cognitive benefit. Gantenerumab and crenezumab, which targeted different forms of aggregated amyloid, also failed in phase 3.25PubMed Central. History and progress of hypotheses and clinical trials for Alzheimer’s disease
Each failure refined the field’s understanding. The emerging consensus is that not all forms of amyloid-beta are equally toxic, that the timing of intervention matters enormously, and that clearing amyloid alone is insufficient if too much downstream damage from tau tangles and neurodegeneration has already occurred. The drugs that finally showed benefit, lecanemab and donanemab, targeted toxic aggregated forms of amyloid more selectively and enrolled patients at earlier disease stages than most predecessors did. Those twin refinements appear to have been the key.
Getting Antibodies Into the Brain
One fundamental challenge with all antibody therapies for brain diseases is that antibodies are large molecules, and the blood-brain barrier exists specifically to keep large molecules out. Only a tiny fraction of an intravenously infused antibody actually reaches the brain. This means high systemic doses are needed, which contributes to side effects and cost.
A next-generation approach uses bispecific antibodies, molecules engineered with two functional arms. One arm targets amyloid-beta (or another disease-related protein), while the other arm latches onto transferrin receptor 1, a protein on blood-brain barrier cells that naturally shuttles iron-carrying transferrin into the brain. By hitching a ride on this transport system, bispecific antibodies can cross the barrier more efficiently, achieving higher and more evenly distributed brain concentrations than conventional antibodies at lower doses.26The Journal of Prevention of Alzheimer’s Disease. Review Bispecific brain-penetrant antibodies for treatment of Alzheimer’s disease Preclinical studies have shown that this shuttle strategy enhances amyloid plaque clearance.27PubMed Central. Transferrin receptor-binding blood-brain barrier shuttle enhances brain delivery and plaque-clearing efficacy of a therapeutic anti-Aβ antibody Perhaps equally important, improved brain penetration at lower doses could reduce ARIA risk, since the vascular disruption that causes ARIA is partly dose-dependent.28The Journal of Prevention of Alzheimer’s Disease. Review Bispecific brain-penetrant antibodies for treatment of Alzheimer’s disease
Beyond Amyloid: Antibodies Targeting Tau and Microglia
Amyloid is only one part of the Alzheimer’s puzzle. Tau protein, which forms tangles inside neurons, is closely linked to the actual pace of cognitive decline. Several monoclonal antibodies targeting tau have entered clinical trials. Early-phase safety studies have generally gone well, but two phase 2 trials in progressive supranuclear palsy and other primary tau diseases were halted for lack of efficacy. One interpretation is that antibodies targeting only the tau that exists outside neurons may be insufficient, since the vast majority of pathological tau sits inside cells at concentrations thousands of times higher than what leaks into the fluid surrounding them. The most effective next-generation tau antibodies may need to enter neurons directly.29PubMed Central. Current Status of Clinical Trials on Tau Immunotherapies
Another intriguing approach targets the brain’s own immune cells rather than the disease proteins themselves. TREM2 is a receptor on the surface of microglia that acts like an activation switch. When TREM2 is stimulated, microglia become more effective at clearing both amyloid and tau. Researchers have developed agonistic monoclonal antibodies, ones that activate TREM2 rather than blocking a target, and preclinical work has shown that these can reduce tau burden and attenuate neurodegeneration in animal models.30PubMed Central. TREM2 Agonism with a Monoclonal Antibody Attenuates Tau Pathology and Neurodegeneration Other groups have engineered TREM2-activating antibodies with dramatically enhanced potency through structural modifications.31PubMed. A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimer’s disease These are still in early development, but the logic is appealing: rather than sending in an external cleanup crew, you train the brain’s resident cleanup crew to do a better job.
How Diagnosis Is Changing Alongside Treatment
For most of Alzheimer’s history, confirming the presence of amyloid plaques required either a PET brain scan (expensive and not widely available) or an autopsy. That diagnostic bottleneck made it difficult to identify the patients who would be appropriate candidates for amyloid-targeting therapy. The development of blood-based biomarker tests is changing this. Until recently, the presence of amyloid in the brain of someone with cognitive symptoms could not be confirmed without advanced imaging, forcing clinicians to make treatment decisions with significant diagnostic uncertainty.32JAMA. What to Know About the First FDA-Cleared Blood Test for Alzheimer Biomarkers
Blood tests that measure amyloid-beta ratios and phosphorylated tau are now reaching clinical use. The FDA has cleared the first blood test for Alzheimer’s biomarkers, which could dramatically expand the number of patients who get an accurate diagnosis early enough to be eligible for treatment. This matters because the current antibody therapies work only in people with confirmed amyloid pathology and early-stage disease. A cheap, accessible screening test could be the difference between these drugs helping thousands and helping hundreds of thousands of people, though it also raises the uncomfortable prospect of identifying far more eligible patients than the healthcare system can currently treat.